NCT00393328View on ClinicalTrials.gov

Bioequivalence Study of Atazanavir 300 mg Capsule

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions
HIV Infections
Interventions
DRUG

Atazanavir + Ritonavir

Capsules, Oral, ATV 300mg as 2-150mg + RTV 100mg, single dose, 7 days washout crossed over to Treatment B.

DRUG

Atazanavir + Ritonavir

Capsules, Oral, ATV 300mg as single cap + RTV 100mg, single dose, 7 days washout.

Trial Locations (1)

Unknown

Local Institution, Hamilton

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY